Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Cagrisema 12mg Pre Filled Pen Fat freeze Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 ScienceDirect Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine